Simon Daniel et al., published this research article in Trends in Biotechnology Journal and explore the application of Quality by Design (QbD) principles to RNA platform production processes. It highlights the critical quality attributes (CQAs) of RNA-based products, focusing on immunogenicity and instability, and explores the complex relationship between product quality and process parameters. The article then delves into advanced analytical and modeling technologies, including process analytical technology (PAT) and digital twins, to enable the design and control of robust and versatile manufacturing processes. The authors propose a future vision for a disease-agnostic RNA platform technology that can rapidly adapt to emerging threats and variants, emphasizing the potential of QbD to unlock the full potential of RNA technology for global vaccination, infectious disease control, and future therapy development.

ManchikatLa Rajam wrote this scientific article in the Journal of BioSciences and examines RNA silencing technology and its potential uses in crop improvement. The article highlights the advantages of RNA interference (RNAi) for developing pest-resistant crops, improving crop quality, and reducing crop losses due to various stresses. The article also discusses the concerns surrounding off-target effects of RNAi technology and the need for risk assessment of transgenic RNAi plants. Finally, the article explores the potential of environmental RNAi, where exogenous dsRNA is used as a spray for pest control, as a non-transgenic alternative.

Rebeca T. Stiepel et al., wrote this article in Bioengineering and Translational Medecine and provides a historical overview of micro- and nanotechnology platforms used in medicine, dating back to the 1790s. The authors classify different technologies based on the materials they use, including inorganic, polymer-based, lipid-based, and cell-based therapies. They then discuss the successes of these platforms, including the rapid development of lipid nanoparticle vaccines for COVID-19, and the efficacy of PEGylation, a technique used to improve the properties of drug carriers. However, they also address the challenges that have hindered the widespread adoption of micro- and nanotechnology, such as the manufacturing complexities, potential toxicity, and immune responses. The authors conclude by highlighting the future potential of these technologies to address important medical needs, including personalized medicine and the rapid development of new therapies for infectious diseases.

Shuai Ding et al., published a scientific review article in the International Journal of Molecular Science that explores the applications of the CRISPR/Cas9 gene editing system in cancer therapy. The review focuses on three primary applications: CRISPR-based CAR-T cell therapy, CRISPR screening techniques for identifying new drug targets and cancer-related genes, and the use of CRISPR for generating cancer models in vitro and in vivo. The authors discuss the CRISPR/Cas9 system's mechanism, its advantages over other gene editing technologies, and its potential benefits for cancer treatment. However, the review also acknowledges the challenges associated with CRISPR/Cas9 technology, including off-target effects, delivery issues, and the potential risk of carcinogenesis. The article highlights the ongoing research efforts to address these challenges and further refine this promising tool for combating cancer.

This research article, published in ACS Central Science in 2021 by Kellie D. Nance and Jordan L. Meier, explores the role of N1-methylpseudouridine (m1Ψ), a modified nucleobase, in the development and effectiveness of COVID-19 mRNA vaccines. The authors highlight the importance of m1Ψ in reducing the immunogenicity of mRNA vaccines, thereby minimizing harmful side effects. They also discuss the potential impact of m1Ψ on mRNA translation, suggesting that it may enhance protein production in some contexts. The article concludes by emphasizing the importance of continued research into RNA modifications for the development of improved mRNA therapies.

This research paper from Anamul Haque published in the International Journal of Pharmaceutics reviews the development and use of lipid nanoparticles (LNPs) as delivery carriers for RNA-based therapeutics. The paper discusses the advantages and disadvantages of LNPs, including their ability to protect RNA from degradation, their strong transfection efficiency, and their low toxicity. The authors also provide a comprehensive analysis of the components of LNP formulations, including ionizable lipids, cholesterol, helper lipids, and PEGylated lipids, and examine the selection of the appropriate molar ratio of lipid components in LNPs. They highlight the use of LNPs in clinical trials for a variety of diseases, such as hereditary amyloidogenic transthyretin amyloidosis, COVID-19, and various cancers. The paper emphasizes the potential of LNPs as a promising therapeutic approach for a wide range of disease

This review article from Mohammad Chehelgerdi and Matin Chehelgerdi, in Molecular Cancer, focuses on the use of RNA-based treatments in the field of cancer immunotherapy. It begins by explaining the mechanisms of action and potential applications of mRNA vaccines, including their advantages over traditional vaccine techniques. The review examines the current state of mRNA vaccine technology and highlights future directions for its development. It then discusses the optimization of mRNA translation and stability, including the use of lipid nanoparticles and other delivery systems. The article analyzes the immunogenicity of mRNA and its paradoxical effects in cancer immunotherapy, emphasizing the importance of properly activating the innate immune system. Finally, the review explores the potential of self-amplifying mRNA vaccines for cancer immunotherapy and concludes with a comprehensive overview of clinical trials and future perspectives on the development of RNA-based treatments in cancer immunotherapy.

This academic review article from Wenshuo Zhou et al., discusses the advancements and applications of RNA vaccines for treating and preventing infectious diseases. It focuses on the three major types of RNA vaccines: conventional mRNA vaccines, circular RNA vaccines, and self-amplifying RNA (saRNA) vaccines. The article explores the history, development, advantages, and challenges of each type of vaccine and examines their effectiveness against diseases like COVID-19, dengue fever, influenza, and respiratory syncytial virus (RSV). It also analyzes various RNA delivery systems, including lipid nanoparticles (LNPs), extracellular vesicles (EVs), protamine, and hydrogels, highlighting their potential in enhancing vaccine efficacy and safety.

This review article from Attila Becskei published in the Computational and Structural Biotechnology Journal examines the impact of temperature on RNA metabolism, covering a broad range of topics from the fundamental principles of RNA folding and degradation to the practical applications of temperature control in biotechnology and forensic science. The authors discuss how temperature affects RNA structure and function, exploring the mechanisms by which cells sense and respond to temperature fluctuations. They explore how RNA thermosensors regulate gene expression and highlight the role of RNA degradation in various processes, including the development of mRNA vaccines and the estimation of the age of bloodstains.

This article, from Vrinda Gote et al., published in the International Journal of Molecular Sciences, provides a comprehensive overview of mRNA vaccines. It covers the structure of mRNA, the role of modified nucleotides, and the mechanisms by which mRNA vaccines stimulate both the innate and adaptive immune systems. The article goes on to examine the use of lipid nanoparticles for mRNA delivery, including different types of lipids and their role in the formulation of LNPs. The authors explore the manufacturing process for mRNA vaccines, highlighting key steps such as upstream production, downstream purification, and formulation. Finally, the article discusses the current status of mRNA vaccines in clinical trials, the development of second-generation mRNA vaccines, and the potential shortcomings of mRNA vaccines.